Skip to main content

Table 2 Summary of tumour responses during the study period for the ITT population*

From: Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non–small-cell lung cancer

Tumour response, n (%) Cisplatin + gemcitabine + axitinib, (n = 38)
Complete response 1 (2.6)
Partial response 14 (36.8)
Stable disease 9 (23.7)
Progressive disease 3 (7.9)
Indeterminate response 8 (21.1)
Not assessed due to early death 2 (5.3)
Baseline status uncertain§ 1 (2.6)
Objective response (complete + partial) 15 (39.5)
  1. ITT = intent-to-treat.
  2. *Study period comprised the treatment period plus 28-day follow-up period after the last dose of study drug.
  3. Imaging scans unavailable or performed >28 days after the last study dose.
  4. Death occurring before the first scheduled tumour assessment.
  5. §No baseline assessment performed.